Vallerie McLaughlin, MD - Judge
University of Michigan, Ann Arbor,  MI

Ioana Preston, MD - Attorney
Tufts Medical Center, Boston, MA

Richard Krasuski, MD – Attorney
Duke University Medical Center, Durham, NC

Sudarshan Rajagopal, MD, PhD - Witness
Duke University School of Medicine, Durham, NC

Hunter Clay Champion, MD, PhD, FAHA - Witness  
Southeastern Cardiology Associates, Columbus, GA

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and TotalCME, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live event for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.01 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008162-9999-21-2998-L01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

This activity is supported by independent educational grants from Actelion Pharmaceuticals US, Inc. and United Therapeutics Corporation.

Jointly provided by TotalCME, Inc & Postgraduate Institute for Medicine.  

For questions please contact impact@mededonthego.com

1. Review the risk assessment-based criteria used to determine the need for PAH treatment escalation
2. Discuss the timing of periodic risk assessment in the PAH patient and whether this comes with a “one size fits all” strategy with
respect to current goals of treatment
3. Debate whether delaying treatment escalation buys time or is a formula for increasing PAH patient mortality/morbidity risk

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Vallerie McLaughlin, MD - Consulting fees: Acceleron, Actelion, Altavant, Caremark LLC, Civi Biopharma Inc, Gossamer Bio, Liquida, United Therapeutics; Contracted research: Acceleron, Actelion, Gilead, Sonovie, Reata, United Therapeutics

Ioana Preston, MD - Consulting fees: Acceleron, Actelion, Liquidia, Pfizer, United Therapeutics, Respira, Gossamer; Contracted research:Acceleron, Actelion, United Therapeutics, PhaseBio

Richard Krasuski, MD- Consulting fees: Actelion Pharmaceuticals, CryoLife; Contracted research: The Adult Congenital Heart Association, Actelion Pharmaceuticals, Corvia, CryoLife, Edwards Lifescience

Sudarshan Rajagopal, MD, PhD - Receipt of Intellectual Property Rights/Patent Holder: Polarean; Consulting fees: Janssen, United Therapeutics, Altavant, Liquidia, Insmed, APIE; Contracted research: Janssen, United Therapeutics, Analytics4Life, Altavant
Therapeutics, Bayer

Hunter Clay Champion, MD, PhD, FAHA - Consulting fees: United Therapeutics, Janssen/Actelion, Bayer, Acceleron; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: United Therapeutics, Janssen/Actelion, Bayer

The PIM planners and managers have nothing to disclose.
The TotalCME planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

This activity is FREE to all participants.

This activity has been designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with pulmonary hypertension. 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.